Patients fulfilling clinical and neuroimaging criteria for NMOSD but testing negative for AQP4-IgG should be re-evaluated for differential diagnoses, including MS and MOGAD (Figures 2, 3). This evidence concerns the gene AQP4 and myeloid sarcoma.